epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   226 Trials   226 Trials   3828 News 


12345678910111213...4950»
  • ||||||||||  letrozole / Generic mfg., epirubicin / Generic mfg.
    Journal:  Gastric metastasis and peritoneal carcinosis revealing primary breast cancer: an unusual presentation. (Pubmed Central) -  Jun 17, 2024   
    Further investigations led to bilateral invasive lobular breast carcinoma diagnosis. Epirubicin cycophosphamide was prescribed after progression under letrozole ribocilib therapy.This case aims to raise awareness among clinicians about the importance of ruling out breast cancer in patients with peritoneal carcinosis and paying attention to digestive symptoms in breast cancer patients with careful gastric endoscopic examination to avoid misdiagnosis.
  • ||||||||||  Journal:  Cancer Therapies and Cardiomyocyte Viability: Which Drugs are Directly Cardiotoxic? (Pubmed Central) -  Jun 1, 2024   
    Some of those, have not been associated with clinical cardiotoxicity, while others, known to be cardiotoxic do not appear to mediate it via direct effects on cardiomyocytes. More detailed investigations of the effects of cancer therapies on various cardiovascular cells should be performed to comprehensively determine the mechanisms of cardiotoxicity.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy. (Pubmed Central) -  May 27, 2024   
    In this system, Epirubicin (EPI) as an immunogenic cell death (ICD) inducer was coupled to a branched glycopolymer via hydrazone bonds and diABZI as a stimulator of interferon genes (STING) agonist was encapsulated into mB4S...Treatment with mB4S in combination with an anti-PD-L1 antibody elicited potent immune responses by increasing the ratio of matured dendritic cells (DCs) and CD8+ T cells, promoting cytokines secretion, up-regulating M1-like tumor-associated macrophages (TAMs) and down-regulating immunosuppressive myeloid-derived suppressor cells (MDSCs). Therefore, this nanosystem for co-delivery of an ICD inducer and a STING agonist achieved promotion of DCs maturation and CD8+ T cells infiltration, creating an immuno-supportive microenvironment, thus potentiating the therapy effect of the anti-PD-L1 antibody in both 4T1 breast and CT26 colon tumor mice.
  • ||||||||||  peposertib (M3814) / EMD Serono
    Preclinical, Journal:  Peposertib, a DNA-PK Inhibitor, Enhances the Anti-Tumor Efficacy of Topoisomerase II Inhibitors in Triple-Negative Breast Cancer Models. (Pubmed Central) -  May 25, 2024   
    We established a well-tolerated preclinical treatment regimen combining peposertib with pegylated liposomal doxorubicin (PLD) and demonstrated strong anti-tumor efficacy in cell-line-derived and patient-derived TNBC xenograft models in vivo. Taken together, our findings provide evidence that co-treatment with peposertib has the potential to enhance the efficacy of anthracycline/TOPO II-based chemotherapies, and it provides a promising strategy to improve treatment outcomes for TNBC patients.
  • ||||||||||  Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
    Trial completion date:  NeoTENNIS: Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients (clinicaltrials.gov) -  May 21, 2024   
    P2,  N=70, Active, not recruiting, 
    Finally, the UiO-66-NH2/GO/SPGE sensor was successfully utilized for the quantitative analysis of EP and TP in pharmaceutical injection, yielding highly satisfactory results. Trial completion date: Dec 2023 --> Dec 2025
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy. (Pubmed Central) -  May 10, 2024   
    Epirubicin (EPI) alone can trigger mildly protective autophagy in residual tumor cells, resulting in an immunosuppressive microenvironment...This indicated that the SA&EA nanoplatform has better therapeutic efficacy than the single STF@AHMPP and EPI@AHMPTP groups. This research provided a way to set up a redox-triggered autophagy-induced nanoplatform with PD-L1 inhibition to enhance chemo-immunotherapy.
  • ||||||||||  Induction chemotherapy followed by CCRT or RT for patients with esophageal cancer (Lomond Auditorium) -  May 8, 2024 - Abstract #ESTRO2024ESRTO_60;    
    Preliminary results of our IndCT followed by CCRT/RT are feasible for esophageal cancer with encouraging preliminary outcome. This novel protocol deserves to study in future trials to compare with the standard neoadjuvant CCRT followed by surgery.
  • ||||||||||  epirubicin / Generic mfg.
    Preclinical, Journal:  Effect of Transarterial Chemotherapy on the Structure and Function of Gut Microbiota in New Zealand White Rabbits. (Pubmed Central) -  Apr 26, 2024   
    Following transarterial chemotherapy with epirubicin, the Firmicutes abundance decreased, whereas that of Proteobacteria increased...Hepatic arterial chemotherapy induces dysbiosis of the intestinal microbiota, disrupts intestinal barrier function, damages the integrity of the intestinal mucosa, increases intestinal permeability, facilitates excessive passage of harmful substances through the gut-liver axis communication between the liver and intestine, and triggers activation of inflammatory pathways such as LPS-TLR-4-pSTAT3, ultimately leading to an inflammatory response. This study provides a theoretical basis for combining TACE with targeted GM intervention to treat HCC and reduce adverse gastrointestinal reactions.
  • ||||||||||  capecitabine / Generic mfg.
    Efficacy and safety of concurrent capecitabine and radiotherapy as adjuvant treatment in triple negative breast cancer. () -  Apr 24, 2024 - Abstract #ASCO2024ASCO_5146;    
    We prospectively analyzed 24 patients with triple negative breast cancer with residual disease after dose dense neoadjuvant chemotherapy with Epirubicin and Cyclophosphamide and Docetaxel (in some cases with carboplatin) who received concurrent Capecitabine and radiotherapy in adjuvant setting. Capecitabine concurrent with radiotherapy appears to be very efficacious and safe in the adjuvant treatment of breast cancer, especially in preventing local recurrence.
  • ||||||||||  Optimization of intra-peritoneal chemotherapy: Randomized phase II GERCOR CHIMOVIP study. (E451) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1821;    
    P2
    However, patients with high FAD activity might have a better tumor response and survival benefit to SoraTACE than SoraHAIC. Cisplatin, the platinum salt recommended for IP administration of chemotherapy, was administered with epirubicin, chosen over paclitaxel to prevent neuropathy...In the control arm patients received 6 cycles of IV carboplatin AUC6 with paclitaxel 80 mg/m
  • ||||||||||  epirubicin / Generic mfg.
    Predicting epirubicin response in Danish patients with breast cancer. (Hall A; Poster Bd #: 131) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1267;    
    The expression of the genes in the signature is highly correlated between microarray- and RNA sequencing data. Moving forward, we will seek to validate the model independently on RNA sequencing data.
  • ||||||||||  Adjuvant chemotherapy guided by an integrated mRNA (Hall A; Poster Bd #: 117) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1253;    
    P2/3
    The multigene signature showed potential for tailoring adjuvant chemotherapy for patients with operable TNBC. Intensive regimens incorporating GP into anthracycline/taxane-based therapy improves survival with manageable toxicity.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  Annexin-A5 Overexpression Increases Sensitivity of MCF-7 and MCF-7/ADR Cells to Epirubicin. (Pubmed Central) -  Apr 12, 2024   
    ANXA5 overexpression alone or combined with EPI treatment increased the apoptosis of MCF7 and MCF7-ADR cells. The results of the present study demonstrate that ANXA5 overexpression increases the sensitivity of MCF-7 and MCF-7/ADR to EPI, suggesting a possible beneficial role of ANXA5 in the therapy of BC.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Immunotherapy based hybrid TACE in multifocal HCC outside Milan criteria via hepatic and phrenic arteries () -  Apr 10, 2024 - Abstract #ECIO2024ECIO_378;    
    Combination or loading of lipiodol with Epirubicin and Bevacizimab for cTACE and DEB-TACE (Hepaspheres) is possible and appears to be successful. However, stability testing, delivery dose and sideeffects is not known for Bevacizumab loading.Take-home points Successful treatment using combined balloon-occlusion based cTACE and DEB-TACE outside Milan criteria with Epirubicin and Bevacizumab loading is possible.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis. (Pubmed Central) -  Apr 5, 2024   
    Additionally, the FOXP3 inhibitor epirubicin exhibited the ability to impede proliferation and induce ferroptosis in GBM cells both in vitro and in vivo. In summary, our study provided evidences that FOXP3 facilitates the progression of glioblastoma by inhibiting ferroptosis via the linc00857/miR-1290/GPX4 axis, highlighting FOXP3 as a potential therapeutic target for GBM.
  • ||||||||||  5-fluorouracil / Generic mfg.
    Journal:  Anthracycline-based hepatic arterial infusion chemotherapy achieved 17 (Pubmed Central) -  Mar 25, 2024   
    The in vitro and in vivo results of our study indicate that the concurrent use of Epirubicin with Taxifolin has supportive effects on breast cancer treatment. A 46-year-old woman with estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer who had multiple LMs and bone metastases underwent seven lines of systemic therapy (paclitaxel/bevacizumab for 38
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
    Journal, Metabolomic study:  AI-assisted mass spectrometry imaging with in situ image segmentation for subcellular metabolomics analysis. (Pubmed Central) -  Mar 22, 2024   
    Moreover, we identified that the downregulations of glutamate and aspartate in the malate-aspartate shuttle pathway may contribute to the higher paratoxicity of DOX. Our current AI-SMSI approach has promising applications for subcellular metabolomics analysis and thus opens new opportunities to further explore drug-cell specific interactions for the long-term pursuit of precision medicine.